Table 4.
Tigecycline Minimal Inhibitory Concentrations (MICs) in the absence and presence of efflux pump inhibitors.
| Strain | TGC | TGC + CCCP | TGC + RES | TGC + VER |
|---|---|---|---|---|
| (mg/L) | ||||
| VRE57 | 0.060 | 0.060 | 0.060 | 0.030 |
| VRE65 | 1.000 | 1.000 | 1.000 | 0.250 |
| VRE69 | 1.000 | 1.000 | 1.000 | 0.250 |
| VRE80 | 1.000 | 1.000 | 1.000 | 0.250 |
| VRE109 | 0.060 | 0.030 | 0.060 | 0.030 |
| A1 | 0.060 | 0.030 | 0.060 | 0.030 |
| A11 | 0.125 | 0.125 | 0.125 | 0.030 |
| A20 | 0.500 | 0.500 | 0.500 | 0.060 |
| A42 | 1.000 | 1.000 | 1.000 | 0.125 |
| B1 | 0.060 | 0.060 | 0.060 | 0.030 |
| B21 | 0.250 | 0.250 | 0.250 | 0.030 |
| B42 | 0.500 | 0.500 | 0.500 | 0.125 |
| C1 | 0.060 | 0.030 | 0.060 | 0.030 |
| C6 | 0.125 | 0.125 | 0.125 | 0.06 |
| C42 | 1.000 | 1.000 | 0.500 | 0.125 |
| VRE109(pAT28) | 0.060 | N/A | N/A | N/A |
| VRE109(pAT28-hypVRE80) | 0.125 | N/A | N/A | N/A |
| VRE109(pAT28-rpsJVRE80) | 0.060 | N/A | N/A | N/A |
| OG1RF(pMSP3535) | 0.060 | N/A | N/A | N/A |
| OG1RF(pMSP3535-abcVRE80) | 0.060 | N/A | N/A | N/A |
| VRE109(pAT28-marR VRE109) | 0.060 | N/A | N/A | N/A |
| VRE109(pAT28-marRB42) | 0.125 | N/A | N/A | N/A |
| B42(pAT28) | 1.000 | N/A | N/A | N/A |
| B42(pAT28-marRVRE109) | 1.000 | N/A | N/A | N/A |
| B42(pAT28-marRB42) | 2.000 | N/A | N/A | N/A |
TGC: tigecycline; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; RES: reserpine; VER: verapamil; N/A: not applicable.